Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101

Beam Therapeutics Inc.

2022-Q3 EPS reported -$3.59 revenue$40,883,000

Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.
Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2022, up from $965.6M.
Patient recruitment underway in BEACON trial for BEAM-101; first sickle cell patient enrollment expected by year-end 2022.
BEAM-302 nominated as development candidate for alpha-1 antitrypsin deficiency; targeting in vivo DNA correction of E342K mutation.
BEAM-201 IND response submitted to FDA after clinical hold; no BEAM-102 IND filing in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.